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STUDY QUESTION: How did the field of stem cell research develop in the years following the derivation of the first human embryonic
stem cell (hESC) line?
SUMMARY ANSWER: Supported by the increasing number of clinical trials to date, significant technological advances in the past two dec-
ades have brought us ever closer to clinical therapies derived from pluripotent cells.
WHAT IS KNOWN ALREADY: Since their discovery 20 years ago, the use of human pluripotent stem cells has progressed tremendously
from bench to bedside. Here, we provide a concise review of the main keystones of this journey and focus on ongoing clinical trials, while
indicating the most relevant future research directions.
STUDY DESIGN, SIZE, DURATION: This is a historical narrative, including relevant publications in the field of pluripotent stem cells
(PSC) derivation and differentiation, recounted both through scholarly research of published evidence and interviews of six pioneers who par-
ticipated in some of the most relevant discoveries in the field.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The authors all contributed by researching the literature and agreed upon
body of works. Portions of the interviews of the field pioneers have been integrated into the review and have also been included in full for
advanced reader interest.
MAIN RESULTS AND THE ROLE OF CHANCE: The stem cell field is ever expanding. We find that in the 20 years since the derivation
of the first hESC lines, several relevant developments have shaped the pluripotent cell field, from the discovery of different states of pluripotency,
the derivation of induced PSC, the refinement of differentiation protocols with several clinical trials underway, as well as the recent development
of organoids. The challenge for the years to come will be to validate and refine PSCs for clinical use, from the production of highly defined cell
populations in clinical grade conditions to the possibility of creating replacement organoids for functional, if not anatomical, function restoration.
LIMITATIONS, REASONS FOR CAUTION: This is a non-systematic review of current literature. Some references may have escaped
the experts’ analysis due to the exceedingly diverse nature of the field. As the field of regenerative medicine is rapidly advancing, some of the
most recent developments may have not been captured entirely.
WIDER IMPLICATIONS OF THE FINDINGS: The multi-disciplinary nature and tremendous potential of the stem cell field has import-
ant implications for basic as well as translational research. Recounting these activities will serve to provide an in-depth overview of the field,
fostering a further understanding of human stem cell and developmental biology. The comprehensive overview of clinical trials and expert opi-
nions included in this narrative may serve as a valuable scientific resource, supporting future efforts in translational approaches.
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Introduction
In 1998, a report published in the scientific journal Science marked the
beginning of the modern era of regenerative medicine (Thomson et al.,
1998). For the first time, scientists were able to derive stem cells from
a human embryo and show that these cells could be maintained in the
so-called pluripotent state.
Pluripotency is a unique characteristic of stem cells; a pluripotent
cell can divide indefinitely into daughter cells, while at the same time
retaining the capacity to differentiate into any cell type of the human
body when submitted to the appropriate stimuli. Human embryonic
stem cells (hESCs) are pluripotent, and their derivation sparked new
possibilities, from the production of ‘spare parts’ to treating a plethora
of degenerative conditions, the study of early embryonic development,
to revolutionizing drug screening and development and broadening
the spectrum of human toxicology research.
In the 20 years since, some of these promises have been fulfilled,
some roadblocks have appeared and some new players have entered
the stage of pluripotency. The aim of this review is to tell the story of
this amazing journey and to reveal its most salient moments through
the voice of some of the pioneers in this exciting field.
Materials andMethods
The literature search for the preparation of this non-systematic review
was carried out in PubMed including articles written in English between
1998 and 2018. Moreover, suggestions from the pioneers interviewed on
seminal contributions were included in the paper. Further, reports in the
media were scanned to include up to date information for topics not
always reported in the scientific literature. Finally, the database
ClinicalTrials.gov and other Clinical Trials Registries were scanned for rele-
vant ongoing trials.
The derivation of the first hESC line
In the mid-90s of the last century, one of the most active centers of stem
cell research, at that time restricted to mouse work in most countries, was
the Wisconsin National Primate Research Center in the USA. It was here
that scientists had derived in 1994 the first primate ESC line from rhesus
macaque embryos. As customary at the time, the line was cultured over a
feeder layer of mouse fibroblasts and the scientists were able to show the
cells ability to continually grow in culture for more than 1 year. Moreover,
once released from stem cell culture condition and injected into immuno-
deficient mice these cells could differentiate spontaneously into derivatives
of the three germ layers: endoderm, ectoderm and mesoderm, a test of
pluripotency still used to this day (Thomson et al., 1995).
Without any doubts, their experience with rhesus ESCs accelerated
their learning curve in primate stem cell handling, and the same team of
scientists led by Dr J. A Thomson was able to report, 4 years later, the der-
ivation of the first hESC line (Thomson et al., 1998) (Fig. 1). The research-
ers used 36 embryos from patients who underwent IVF, who donated
their embryos after completing their treatment. From those embryos, 14
inner cell masses (ICMs) were isolated, and five hESC lines were derived
(Fig. 2). It is interesting to note that one of those lines, H9, has been used
in clinical trials several years following its derivation.
Around the same time, hESC derivation was also attempted at the
National University Hospital in Singapore. In 1994, Bongso et al. cultured
whole blastocysts on human tubal ampullary epithelium and succeeded in
WHATDOES THIS MEAN FOR PATIENTS?
We reviewed the history of human pluripotent stem cell (hPSC) derivation, in the context of the scientific and technical environment at
the time, giving a historical account of the development of the field of stem cell research with a special emphasis on regenerative medicine
and clinical applications. Furthermore, we organized interviews with several stem cell scientists at the forefront of basic and clinical
research to give the reader a qualitative account of the field, as well as a perspective on the future developments at the cutting edge of
research.
This 20th anniversary of the derivation of human embryonic stem cell (hESC) lines offers an ideal opportunity to look back over the past 20
years in this field, as well as to look forward to what the future may hold. With this review, we hope to inspire young investigators today to con-
tinue working on their research in this fascinating topic.
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Figure 1 Historical timeline of human embryonic stem cells. hESCs: human embryonic stem cells, hiPSC: human-induced pluripotent stem cells,
CRISPR/Cas 9: clustered regularly interspaced short palindromic repeat/ CRISPR associated 9.
Figure 2 Types of human pluripotent stem cells. Three pathways to the generation of pluripotent cells are described: hESC derivation from
preimplantation-stage embryos (hESC; top), derivation after somatic cell nuclear transfer (SCNT-SC; middle) and derivation through reprogramming
of somatic cells (iPS; bottom). SCNT-SC: somatic cell nuclear transfer-stem cells; iPS: induced pluripotent stem cells.
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obtaining cells that retained stem cell-like morphology (Bongso et al.,
1994). Although these cultures differentiated after several passages, this
was the first report of the successful isolation of human ICM cells and their
continued culture in vitro. A few years later, in 2000, Reubinoff et al., inde-
pendently reported the establishment of hESC lines with similar properties
to those of Thomson et al. (1995), obtaining ICM clusters from human
blastocysts using immunosurgery and culturing them on mouse embryonic
fibroblasts. Their report further validated the potential of hESCs by dem-
onstrating that they could be directed toward the neuronal lineage,
through isolation and culture of neuronal progenitor cells from differentiat-
ing hESCs. Dr A. Trounson, a pioneer in the field, offers his testimonial:
‘When Martin Pera joined me from Oxford he thought we had human
ESCs, so I sent Ben Reubinoff (our PhD student) to Singapore to make
them again. He brought back some of the colonies, which converted to
hESCs and we set about characterizing them, using markers Martin had for
setting up the teratoma assays, just before we received the Thomson
paper for review.’ (Supplementary data).
This research certainly paved the way for the large number of pluripo-
tent stem cell lines produced to date and generated considerable optimism
regarding stem cell biology. Notably, the scientific and medical potential of
hESCs could not have been realized without the progress made in the field
of assisted reproduction at the time, and particularly the use of surplus IVF
embryos, donated by patients for research purposes.
The news and promise of hESCs sparked the imagination of scientists
and the general public alike, and the race to repeat the results was fierce,
compiled by the fact that very few researchers had at the time seen pri-
mate stem cells. As Dr M. Stojkovic, whose team derived the first hESC
line in the UK, recalls: ‘I remember very well the following picture: in the
front of our microscope was Thomson’s paper and images of hESC col-
onies and Majlinda Lako and myself starting our open-air work: cutting the
colony, passaging the cells… both of us had never seen or worked with
hESCs before.’ (Supplementary data).
The hope that stem cells could provide potential therapies in regenera-
tive medicine prompted further research toward the directed differenti-
ation of hESCs toward specialized cell types (Trounson, 2006). Derivation
reports showed that suboptimal culture conditions led to spontaneous dif-
ferentiation of hESCs (Reubinoff et al., 2000, Thomson et al., 1998).
Subsequently, Schuldiner et al. demonstrated that the differentiation of
hESCs in vitro could be controlled by using several factors to enrich for spe-
cific embryonic germ layers (Schuldiner et al., 2000). This work provided a
valuable framework for the directed derivation of a number of specialized
cell types from hESCs, including mature neurons (Reubinoff et al., 2001,
Zhang et al., 2001), cardiomyocytes (Kehat et al., 2001, Mummery et al.,
2003) and insulin-producing cells (Assady et al., 2001). These early reports
were fundamental for further in vitro manipulations of pluripotent stem
cells (PSCs), setting the stage for future clinical applications.
Induced PSCs
In 2006, the PSC field was revolutionized again by the generation of
induced PSC (iPSC), a technology pioneered by Dr S. Yamanaka’s lab in
Kyoto, Japan. Yamanaka’s team demonstrated that forced expression of
four transcription factors (Pou5f1, pou class 5 homeobox 1; Sox2, SRY-
Box 2; Klf4, kruppel like factor 4 and c-Myc, c-myc) could reprogram adult
mouse cells into a pluripotent state remarkably similar to that of ESCs
(Fig. 2) (Takahashi and Yamanaka, 2006). Less than 1 year later, the same
technology was used for the derivation of human iPSCs (hiPSCs)
(Takahashi et al., 2007; Yu et al., 2007), providing an alternative source of
human pluripotent stem cells (hPSCs) without the need to use human
embryos, thus alleviating some of the ethical concerns associated with
hESCs (Fig. 1). The profound impact of iPSC technology on the study of
cell biology, and especially nuclear reprogramming, was recognized when
Dr S. Yamanaka, along with Dr J. Gurdon, received the Nobel Prize for
Physiology or Medicine in 2012 (Fig. 1). Interestingly, when asked about
the name iPSC, S. Yamanaka explained: ‘In naming iPS cells, I used a small
letter for “i” after the model of “iPod” hoping that the name would be easy
to be remembered.’ (Supplementary data).
The initial methods for iPSC derivation used retroviral or lentiviral vec-
tors to deliver the four reprogramming factors (Takahashi et al., 2007; Yu
et al., 2007), which resulted in the integration of the foreign DNA into the
host cell genome, thus carrying the risk of insertional mutagenesis. To
overcome this issue, various non-integrating methods for human iPSC gen-
eration have been developed, including episomal DNA plasmids (Okita
et al., 2011a), Sendai virus (Fusaki et al., 2009), adenovirus (Stadtfeld et al.,
2008), synthesized modified mRNAs (Warren et al., 2010) and proteins
(Kim et al., 2009). Several cell sources and combination of fewer, or differ-
ent, factors have also been successfully used for reprogramming, making it
safer and more efficient in the process (reviewed in (Takahashi and
Yamanaka, 2016)).
One of the main advantages of human iPSCs is their potential to model
disease in vitro. In contrast to hESCs, which can also carry a genetic disease
but are derived from embryos after PGD, the genotype of iPSCs can be
directly linked to the disease phenotype in the patient/cell donor. iPSCs
can be derived from patients carrying a disease-causing mutation and dif-
ferentiated into disease-relevant cell types, offering an unlimited source of
cells for studying genotype–phenotype relationships. Already in 2009, the
derivation of patient-specific iPSCs from a child with spinal muscular atro-
phy showed disease-related deficits in the motor neurons generated
in vitro (Ebert et al., 2009). Since then, an increasing number of disease
models with iPSCs have been generated, especially for monogenic dis-
eases, such as Rett syndrome (Marchetto et al., 2010) and type 2 long QT
syndrome (Itzhaki et al., 2011), but also for genetically complex or sporadic
diseases, such as Alzheimer’s disease (Israel et al., 2012) and Parkinson’s
disease (Nguyen et al., 2011). hiPSCs can successfully recapitulate disease
pathogenesis in vitro and are now increasingly used for validating and
screening new therapeutic compounds (reviewed in (Suh, 2017)). In add-
ition, iPSCs hold great promise for developing personalized treatments.
Patient-specific iPSCs may be used for predicting the patient’s response to
specific treatment strategies, as was indicated in a recent study that
showed concordant results for pharmacological response between iPSCs
and a patient with type 3 long QT syndrome (Malan et al., 2016).
Furthermore, iPSCs may be used in regenerative medicine either as an
autologous cell source or as a HLA-matched allogeneic cell source for
transplantation, minimizing the risk of rejection and the use of long-term
immunosuppression. In 2014, the first clinical study using hiPSC-derived
cells was initiated (Fig. 1).
Somatic cell nuclear transfer derived stem
cells
Somatic cell nuclear transfer (SCNT), colloquially known as cloning, is the
process of transferring the nuclear DNA of a donor somatic cell into an
enucleated oocyte, followed by embryo development (Fig. 2) (Wilmut
et al., 2002). When the SCNT embryo is transferred to a surrogate recipi-
ent with the aim to achieve a live birth, the process is defined as reproduct-
ive cloning. The first success in mammals was achieved with the birth of
Dolly the sheep in 1996 (Wilmut et al., 1997), cloned from a differentiated
mammary epithelial cell. This successful attempt proved that it is possible
to revert the differentiated status of the somatic nucleus to totipotency
(reprogramming) (Wilmut et al., 2002). However, when pluripotent SCNT
stem cells are harvested from the reconstructed SCNT embryo, the pro-
cess is called therapeutic cloning, aiming at deriving pluripotent stem cells
for future cell therapy and research purposes (Fig. 2). The advantage of
therapeutic cloning over ESCs is that SCNT stem cells, like iPSCs, are
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genetically identical to the somatic cell they are derived from, thereby
overcoming immune rejection, inherently valuable for future clinical appli-
cations. Somatic cell nuclear transfer was first attempted in amphibians
due to the comparatively large size of the eggs, enabling easier micromani-
pulation coupled with the possibility of using considerable numbers of eggs
and embryos. Tadpoles developed following transfer of nuclei from early
cleavage stage embryos to enucleated eggs (Briggs and King, 1952).
Subsequently, the group of Dr J. Gurdon (Gurdon et al., 1958) trans-
planted the nucleus of a tadpole intestinal cell into an enucleated frog
egg, succeeding in the creation of viable tadpoles that were genetically
identical to the one from which the intestinal cell was obtained. This
was the first experiment to show that differentiated cells could be set
back to an embryonic state.
Since Dolly, several attempts have been made to generate SCNT-ESCs
in several mammalian species, due to their potential benefits in biomedical
applications such as allo-transplantation and personalized drug selection
(Matoba and Zhang, 2018). These attempts have further enabled optimiza-
tion of the SCNT process, including cell cycle synchronization between
donor cells and recipient oocytes, erasure of epigenetic marks by using
donor cells of varying ages and from different tissues, as well as the add-
ition of small molecules and the modification of culture conditions (Akagi
et al., 2011). The first primate SCNT-ESCs were derived in the rhesus
macaque from adult skin fibroblasts, partly owing to the non-invasive
removal of the spindle-chromosome complex by polarized microscopy
(Byrne et al., 2007). Although very successful in all species tested, pseudo-
blastocyst development following human SCNT was not achieved, with
most SCNT embryos arresting at the stage of embryonic genome activa-
tion (Heindryckx et al., 2007). The first successfully reconstructed human
SCNT pseudoblastocysts were reported by French et al. (2008), however
the derivation of SCNT-ESC lines was not attempted. The key to success
was minor SCNT technological adjustments and the use of in vivo matured
oocytes from young donors. Subsequently, Noggle and collaborators
adjusted the conventional SCNT approach by transferring the somatic
nucleus into a non-enucleated recipient oocyte. The reconstructed
embryos developed well, and several SCNT-ESC lines were derived, albeit
triploid (Noggle et al., 2011).
The group of Dr S. Mitalipov (Tachibana et al., 2013) was the first to
succeed in the production of SCNT-hESCs lines (Fig. 1), later reproduced
by a handful of groups (Chung et al., 2015; Wolf et al., 2017). As S.
Mitalipov highlights himself: ‘We demonstrated that cytoplasmic factors
present in mature human oocytes are capable of converting the trans-
planted nuclear genomes from somatic cells (skin fibroblasts) to become
“oocyte-like”. We then used such skin-derived oocytes to develop into
blastocysts and ESCs.’ (Supplementary data).
The biggest hurdle for human SCNT applications remains the scarcity of
human oocytes. A highly debated research question is whether the SCNT-
ESC represent a better reprogramming method compared to iPSC
(Matoba and Zhang, 2018). An issue of SCNT-ESCs and iPSCs is their pro-
pensity to retain a so-called somatic epigenetic memory, i.e. a partial epi-
genetic state, characteristic of the somatic cell used to derive them, which
may lead to biases or limitations in their fate choice following differenti-
ation into cells of a particular lineage, as shown in the mouse. In-depth ana-
lysis of mouse SCNT-PSCs has shown that they are molecularly closer to
and functionally indistinguishable from mESCs derived from IVF-fertilized
embryos, as compared to both mouse and hiPSCs (Ma et al., 2014; Mishra
et al., 2018).
Toward clinical-grade hPSCs: development
of fully defined culture conditions
Currently, thousands of hPSC lines have been derived and are available for
research purposes (https://hpscreg.eu/; https://cells.ebisc.org; http://
www.hipsci.org/). However, most of these lines are not suitable for clinical
use as they have been derived and maintained in complex and poorly
defined culture systems containing several xenogeneic components.
Conversely, clinical-grade hPSC need to be generated and maintained in
fully defined, xeno-free culture conditions, in compliance with current
good manufacturing practices (GMPs).
The importance of clinical-grade cells has been recognized for several
years now, as expressed in the words of pioneer Dr O. Hovatta: ‘[…] we
saw that the hESC lines derived using mouse cells as feeder cells, and using
bovine serum and other ingredients with animal origin in the culture
medium, were quite suboptimal in quality thinking of infection risks and
functional quality in clinical work. Hence, we decided to develop better
derivation systems.’ (Supplementary data).
In fact, as mentioned by Dr O. Hovatta, the first methods described for
the derivation of hESC entailed the use of mouse feeder cell layers and
medium containing fetal bovine serum (FBS), two factors that may contain
animal pathogens and immunogens. FBS can be replaced by Knock-Out
Serum Replacement (SR), which contains several amino acids, vitamins,
antioxidants and trace elements, but also proteins including lipid-rich albu-
min which seems to play an important role in hPSC self-renewal (Garcia-
Gonzalo and Izpisua Belmonte, 2008). Although more defined than FBS,
SR is still xenogeneic and therefore maintains the risk for pathogenic con-
tamination of hPSCs, which may be transmitted to patients upon trans-
plantation (Martin et al., 2005). The use of human cells, mainly foreskin
fibroblast cells, as feeder layers was the first important step toward xeno-
free hPSC cultures (Richards et al., 2002; Amit et al., 2003; Hovatta et al.,
2003). However, if used for clinical-grade hPSC derivation and culture, the
human feeder cells must also be produced under current GMP conditions
(Prathalingam et al., 2012).
The first feeder-free hESC derivation was reported in 2005, using extra-
cellular matrix extracted from mouse embryonic fibroblasts (Klimanskaya
et al., 2005). They applied a serum-free medium with high concentrations
of basic fibroblast growth factor (bFGF) to support hESC growth in the
absence of fibroblasts. One year later, Ludwig and colleagues composed
the first defined hESC derivation and culture medium, termed TeSR1. The
formulation of the medium was created by testing the effect on hESC
marker expression after the systematic addition of growth factors. One of
the major advantages of this approach was that bFGF and transforming
growth factor β 1 (TGFβ1), important factors for hESC maintenance, were
identified. These factors are significantly different than those that were
known for mouse ESCs (mESC) (Ludwig et al., 2006). Ludwig and collea-
gues also generated an artificial human extracellular matrix with a combin-
ation of human collagen IV, laminin, fibronectin and vitronectin to support
hESC derivation and long-term culture. These conditions, for the first time,
completely eliminated the use of animal products (Ludwig et al., 2006)
(Fig. 1). Further progress in the study of the interactions between different
media components led to the formulation of a completely chemically-
defined albumin-free medium, composed of eight factors: Essential 8
medium (E8). E8 is composed of insulin, selenium, transferrin, L-ascorbic
acid, bFGF and TGFβ (or Nodal) in DMEM/F12 with pH adjusted with
NaHCO3 (Chen et al., 2011).
The first surface coatings used to substitute feeder cells were often pro-
tein mixtures obtained from cell cultures from which the exact compos-
ition can vary significantly from lot to lot (Klimanskaya et al., 2005; Ludwig
et al., 2006). Matrigel, for example, is an extracellular protein mixture
secreted by Engelbreth–Holm–Swarm mouse sarcoma cells, consisting of
structural proteins such as laminin or collagen, growth factors (like TGFβ)
and other proteins in small amounts (Hughes et al., 2010). During their
search for more defined coatings, several groups identified extracellular
matrix proteins with primary roles in supporting hPSC self-renewal and
pluripotency. The recombinant forms of these proteins were then used
for derivation and maintenance of hPSC lines. Known examples are
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vitronectin, laminin and fibronectin (Braam et al., 2008; Rodin et al., 2010).
In 2014, Rodin et al. produced a specific subtype of laminin, LN-521, which
allowed single-cell passaging of hPSC (Rodin et al., 2014), until then only
possible with the use of Rho-associated coiled-coil containing protein
kinase (ROCK) pathway inhibitors (Watanabe et al., 2007). Moreover, the
combination of LN-521 with E-cadherin highly improved the efficiency of
clonal hPSC culture and allowed hESC derivation from single blastomeres
(Rodin et al., 2014).
As an alternative to recombinant proteins, synthetic polymers such as
amino-propylmethacrylamide (APMAAm), poly(methyl vinyl ether-alt-
maleic anhydride) (PMVE-alt-MA) and poly[2-(methacryloyloxy)ethyl
dimethyl-(3-sulfopropyl) ammonium hydroxide] (PMEDSAH) have been
used, resulting in a fully defined surface coating for hPSC culture (Shao
et al., 2015). Finally, physical methods have also been used for surface opti-
mization. Successful hPSC cultures have been described on both oxygen
plasma-etched and UV ozone radiation modified tissue culture polystyrene
(PE-TCP) (Mahlstedt et al., 2010; Saha et al., 2011).
One of the most crucial points of improvement for the future will be the
upscaling of hPSC cultures through 3D systems. Large-scale hPSC produc-
tion will be essential for their successful application in regenerative medi-
cine. The number of cells required for effective cell therapy treatment
varies according to the therapeutic goal but is expected to range between
millions and billions of cells (Serra et al., 2012). While the 2D culture sys-
tems remain time-consuming and labor-intensive, 3D automated culture
systems, e.g. with stirred-tank bioreactors, may provide a solution for the
mass production of high quality hPSC with minimal labor and costs (Steiner
et al., 2010; Fluri et al., 2012; Shafa et al., 2012). To avoid hydrodynamic
stress and agglomeration of growing spherical aggregates, researchers have
attempted to encapsulate hPSCs in hydrogel scaffolds (Li et al., 2018).
With this last approach, systems can be set up that are simple, scalable,
highly efficient, defined and GMP-compatible.
An important aspect to keep in mind is that culture conditions may
affect the genetic and epigenetic stability of the hPSC cells. An elegant
study by Jacobs et al. showed that the decreased pH of the culture
medium, resulting from high-density culture, has a direct influence on
DNA damage and genomic instability of the cells (Jacobs et al., 2016).
Highly recurrent chromosomal abnormalities over culture passages have
been reported by various labs worldwide, reflecting the progressive adap-
tation of hPSCs to culture conditions and the culture advantage conferred
to the cells by these genetic changes (Spits et al., 2008; International Stem
Cell et al., 2011; Nguyen et al., 2013). An example is the duplication of the
long arm of chromosome 20. This abnormality has been reported in ~20%
of hPSC lines worldwide, and culture takeover of the mutant cells is driven
by overexpression of the B-cell lymphoma 2 like 1 (BCL2L1) gene, which
leads to resistance to apoptosis upon dissociation (Avery et al., 2013;
Nguyen et al., 2014). Similarly, also at the epigenetic level, the loss of DNA
methylation and specific histone modifications has been linked to subopti-
mal culture conditions (Nazor et al., 2012; Geens et al., 2016; Geens and
Chuva De Sousa Lopes, 2017).
States of pluripotency: a model of early
embryonic development
In the past two decades, insights into early embryo development have
broadened our perception of pluripotency. As such, pluripotency is no
longer viewed as a fixed state but rather a highly dynamic, malleable signal-
ing network (Wu and Izpisua Belmonte, 2015; Weinberger et al., 2016;
Smith, 2017). Unraveling the complete potency spectrum and its transi-
tions will remain central to our understanding of lineage commitment.
mESCs are one of the earliest and better characterized models of pluri-
potency (Xue et al., 2011). Derived from the ICM of mouse blastocysts,
mESCs demonstrated characteristic features of pluripotency, including
long-term self-renewal, ability to differentiate toward all germ layers, high
single-cell clonogenicity and efficient contribution to chimeras (Evans and
Kaufman, 1981; Martin, 1981) (Fig. 3). hESCs derived from human preim-
plantation embryos, however, were markedly different from mESCs
(Thomson et al., 1998); hESCs had an epithelial morphology, could not be
propagated efficiently as single cells and had different growth requirements
(Thomson et al., 1998). It soon became evident that hESCs rely on different
signaling pathways to maintain pluripotency (Vallier et al., 2005; Nichols and
Smith, 2009) (Fig. 3).
Some years later, mouse epiblast stem cells (mEpiSCs) were isolated
from post-implantation embryos and were found to share many similarities
with hESCs (Brons et al., 2007; Tesar et al., 2007). Their transcriptome
was similar to that of the post-implantation epiblast (Brons et al., 2007;
Tesar et al., 2007), indicating that hESCs were more representative of later
stages of embryo development. Subsequently, two states of pluripotency
were proposed: naive and primed (Nichols and Smith, 2009) (Fig. 3).
Accordingly, mESCs exist in a naive state, which constitutes the functional
in vitro equivalent of the preimplantation epiblast, while hESCs are in a
primed state. The naive or ground state of pluripotency is characterized by
a seemingly unbiased differentiation potential, low variability in pluripo-
tency linked gene expression, global DNA hypo-methylation and two
active X-chromosomes in female cells (Nichols and Smith, 2009; Hackett
and Surani, 2014; Davidson et al., 2015; Van der Jeught et al., 2015;
Weinberger et al., 2016) (Fig. 3). Conversely, cells in the primed state dis-
play distinct pluripotency associated gene patterns, DNA hyper-
methylation, X-chromosome inactivation and inefficiency in forming chi-
meras; this state corresponds to the transition of naive epiblast cells
toward a more committed state in vivo (Nichols and Smith, 2009; Hackett
and Surani, 2014) (Fig. 3).
The notion that pluripotency exists in at least two distinct forms
prompted further research toward the identification of in vitro culture con-
ditions that stabilize the naive state in humans. Naive-like hESCs were first
obtained by transgene-mediated reprogramming of primed hESCs (Hanna
et al., 2010) (Fig. 1). However, the resulting naive hESCs required contin-
ued expression of integrated transgenes for long-term self-renewal. To
address this limitation, several groups attempted to modify the cell culture
conditions in order to induce naive characteristics in hESCs (Xu et al.,
2010; Gu et al., 2012). Soon after, optimized chemically defined conditions
were established, with the naive human stem cell medium (NHSM) allow-
ing rapid conversion of primed hESCs to the naive state (Gafni et al.,
2013). The resulting hESCs retained molecular and functional properties
similar to naive mESCs. In a more systematic approach, Theunissen et al.
identified a combination of five kinase inhibitors that generated hESCs
expressing genes associated with human preimplantation development and
the ground state of pluripotency (Theunissen et al., 2014). However, sev-
eral hESC lines presented with an abnormal karyotype, leading to the
notion that naive hPSCs may be more prone to genomic instability in cul-
ture. Takashima et al. reported that short-term overexpression of
NANOG and kruppel like factor 2 (KLF2) were sufficient to reset the
human pluripotency network (Takashima et al., 2014). To date, several
other conversion protocols have been established (Chan et al., 2013;
Valamehr et al., 2014; Ware et al., 2014; Duggal et al., 2015; Carter et al.,
2016). Derivation of naive hESCs directly from the blastocyst ICM has also
been achieved, albeit generally at low efficiency (Gafni et al., 2013;
Theunissen et al., 2014; Ware et al., 2014) and frequently resulting in an
abnormal karyotype (Theunissen et al., 2014; Guo et al., 2016).
The generation of naive hESCs allowed for their molecular signature to
be described in detail. However, the methods used to generate naive
hESCs vary considerably, restricting the primed state at different molecular
levels. In the embryo, the transition to lineage commitment is highly effi-
cient (Smith, 2017), yet during in vitro culture, altered conditions may mod-
ify this progression, contributing to inconsistent and inefficient directed
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differentiation (Warrier et al., 2017). Notably, current naive hESCs do not
readily differentiate and must first undergo a ‘priming’ step (Takashima
et al., 2014; Irie et al., 2015; Smith, 2017).
The possibility to obtain different types of stem cells illustrates that pluri-
potency is highly determined by the synergistic interplay between embryo
developmental stage and the micro-environment. Considering future
therapeutic applications, unraveling the full potency spectrum of hESCs
may enhance efficiency and control over directed differentiation. Exploring
cellular plasticity during embryogenesis and recapitulating this potential
in vitro will undoubtedly have profound effects on both the reproductive
and stem cell fields.
Differentiation of PSCs
To date, hPSCs have been differentiated to many cell types, either by
directed differentiation (to a specific cell type of interest, for example car-
diomyocytes, dopaminergic neurons or pancreatic beta-cells) or by undir-
ected differentiation (for example in embryoid bodies).
For some purposes, the generation of a single-cell type may be desirable
(e.g. to model heart disease, Parkinson’s disease, diabetes). However, the
initial population of PSCs is usually rather heterogeneous, hence differenti-
ation protocols need constant optimization to increase their efficiency. A
limitation of in vitro differentiation is that the final maturation of differen-
tiated cells in culture is often partial, corresponding to a ‘fetal’ phenotype
instead of a more ‘adult’ (or mature) one. Scientists are still attempting to
identify factors that may be used to mature the cells further. In this sense,
it is important to note that initiatives to help determine the exact ‘matur-
ation level’ of a differentiated cell are emerging. One such initiative is
KeyGenes, a platform that includes transcriptomics data of human fetal
and adult organs and compares the transcriptional profile of differentiated
cells to in vivo organs at different developmental stages (Roost et al., 2015).
For example, this platform was used to demonstrate the fidelity of differen-
tiation of kidney-organoids to the kidney, providing fast and reliable quanti-
fication of the differentiation protocol used and revealing that after 16 days
of differentiation the organoids resembled first trimester kidneys
(Takasato et al., 2015). Another initiative that will surely contribute to
increase our understanding of specific cell types and signals produced at
every stage of maturation to help improve the quality and efficiency of dif-
ferentiation protocols is the Human Cell Atlas project (Rozenblatt-Rosen
et al., 2017) that will generate single-cell transcriptomics data from human
organs.
Organoids and chimeras
More recently, there has been a significant effort to generate human orga-
noids (or mini-organs) by taking advantage of patient-specific PSCs for
drug testing and disease modeling. Organoids are typically free-floating hol-
low spheres made of cells, with self-organizing (and self-patterning) prop-
erties that recapitulate some aspects of development and organ
morphogenesis. Typically, they have epithelial or epithelial and mesenchy-
mal architectural compartments, with the apical part of the epithelial com-
partment on the inside bordering a fluid-filled cavity. Organoids are usually
maintained long-term in defined culture medium on Matrigel-scaffolds.
However, Matrigel is an undefined product, making organoids unsuitable
for regenerative medicine applications. To date, hPSCs have been used to
generate organoids from the digestive system (liver, small intestine,
Figure 3 States of pluripotency: primed vs naive. A comparison between potency states of cells in the developing embryo from mice (top) and
human (bottom) and the in vitro manipulation necessary to maintain/convert each stage to the other. LIF/STAT, leukemia inhibitory factor/signal
transducer and activator of transcription 3; PKCi, protein kinase C inhibitor; E, day of embryonic development; FGF, fibroblast growth factor; ERK,
extracellular regulated kinase.
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stomach), urogenital tract (kidney), neural system (brain, pituitary gland,
inner ear, retina), exo/endocrine glands (mammary glands, thyroid) and
respiratory system (lung) (Huch and Koo, 2015; Kretzschmar and Clevers,
2016; McCauley and Wells, 2017) (Fig. 1). One of the advantages of orga-
noids is the potential for scaling up at an industrial level for translational
applications. With the current screening technologies, organoid systems
could be exploited to model patient-specific drug response to tumorigen-
esis (Arai et al., 2015; Crespo et al., 2017; Qu et al., 2017) or infectious
diseases (Zika virus) (Qian et al., 2016).
In addition to organoids, efforts are also underway to generate fully
grown organs in interspecies-chimeras (organism composed of a mix of at
least two genetically distinct cells), including human–animal chimeras,
broadening the application of patient-specific PSCs. Initial ground-breaking
work from Kobayashi and colleagues in 2010 showed that wild-type rat
PSCs could integrate in mice blastocysts mutants for PDX1 (pancreatic and
duodenal homeobox 1) (that develop to birth but die shortly afterward, as
they lack the pancreas) and resulted in viable PDX1-/- mouse progeny
with a fully functional pancreas made of rat cells (Kobayashi et al., 2010).
This successful application was taken a step further and the technology to
generate pig blastocyst mutants for PDX1 was subsequently developed
(Matsunari et al., 2013). Next steps include investigating whether human
PSCs have the potential to integrate into mutant pig blastocysts, such that
a human pancreas can be developed in the pig. This concept known as
‘organ farming’ may have important implications to resolve the shortage of
organs available for transplantation (heart, kidney, pancreas), as it would
be possible to generate patient-specific human organs in pigs. However,
recent work introducing rat and human PSCs in porcine and bovine blasto-
cysts has demonstrated limited integration and development of chimeric
pig embryos until mid-gestation (Wu et al., 2017) (Fig. 1).
In vitro gamete derivation
Producing gametes in vitro by directed differentiation of hPSCs represent a
complex goal, which may be used in the future to provide for an unlimited
source of in vitro-produced gametes for toxicology and pharmacology stud-
ies, but possibly also for granting certain infertile couples the possibility to
have genetic children.
Germ cell development is a highly orchestrated process, controlled by a
unique set of genetic and epigenetic regulators, taking into account import-
ant variables like primordial germ cell (PGC) state, meiosis and gonadal
somatic cells with important differences between mouse and human mod-
els (Eguizabal et al., 2016). Thus far, researchers have been successful in
deriving in vitro germ cells from mouse PSCs, however many obstacles
remain to be overcome for the robust generation of mature gametes in
humans (Yamashiro et al., 2018).
In vitro differentiation of hPSCs into male
germ cells
An important first step to achieve functional gametes from PSCs is to reach
the PGC state. Putative PGC-like cells have already been derived in vitro
from hPSCs (Fig. 1) (Clark et al., 2004) by several culture approaches such
as embryoid body formation (Bucay et al., 2009), monolayer differentiation
(Tilgner et al., 2008, 2010) or co-culture with fetal gonads (Park et al.,
2009). Also the PGC state can be reached from different pluripotency
states (primed and naive) (Mitsunaga et al., 2017; Sasaki et al., 2015).
The second step for male germ cell differentiation is reaching the
post-meiotic stage of spermatozoa. Unfortunately, differentiation past
the PGC stage has proven challenging in human. One of the strategies
employed includes supplementing the differentiation medium with
growth factors such as bone morphogenetic protein (BMP)-4 (Tilgner
et al., 2008), bFGF, retinoid acid and R115866 (Eguizabal et al., 2011)
and hormones such as insulin and testosterone (Easley et al., 2012).
Several groups have attempted overexpression of specific male germ
cell genes, such as deleted in azoospermia (DAZ), deleted in azoosper-
mia like (DAZL) and BOULE (Kee et al., 2009; Panula et al., 2011) or
VASA (Tilgner et al., 2008, 2010; Medrano et al., 2012) to guide differ-
entiation toward spermatozoa.
Recently, hiPSCs from azoospermic and normospermic males were dir-
ectly transplanted into mouse testis, partially colonizing the testicular niche
and showing signs of early spermatogenesis (Ramathal et al., 2014), raising
the question of whether an initial in vitro differentiation step is needed at
all. In a mouse model, it has been demonstrated that transplanting in vitro-
produced PGC-like cells from PSCs into mouse testis resulted in functional
sperm, capable of producing healthy and fertile offspring (Hayashi et al.,
2011; Nakaki et al., 2013), representing the most important proof of func-
tional male germ cells from PSCs.
So far, the need of a natural testicular niche to obtain mature functional
spermatozoa is still present, and in vitro production of spermatozoa is cur-
rently not possible in humans (Zhou et al., 2016).
In vitro differentiation of hPSCs into female
germ cells
In 2003, Dr H. Schöler´s group demonstrated for the first time that mESCs
were able to form follicle-like structures comprising oocyte-like cells, how-
ever their functionality was not proven (Hubner et al., 2003). Several years
later, in 2012, Hayashi et al. used female mPSCs and induced them into
PGC-like cells, which were then aggregated with fetal ovarian somatic cells
and transplanted under the ovarian bursa. PGC-derived immature oocytes
were obtained and were subsequently matured and fertilized in vitro and
the resulting embryos were transplanted into foster mothers (Hayashi
et al., 2012).
Later, Hikabe et al. reconstituted the complete process of oogenesis
in vitro from mESCs and iPSCs (derived from fetal and adult tail tip fibro-
blasts) to generate oocyte-like cells, however with lower success rates in
comparison to Dr K. Hayashi’s earlier results (Hikabe et al., 2016).
Recently, Jung et al. (Jung et al., 2017) showed that DAZL and BOULE
can modulate hESC entry into meiosis, and that growth differentiation fac-
tor 9 (GDF9) and BMP15 can induce folliculogenesis in differentiated
hESCs. The follicle-like cells derived resembled in vivo primordial follicle, as
proven by transplantation experiments.
At present, robust in vitro production of functional human oocytes from
pluripotent cells remains a distant prospect.
Genetic modifications in hPSCs
Over the past decades, several gene editing strategies have been employed
in hESCs and hiPSCs, each with benefits and limitations.
The first efforts to manipulate the hESC genome involved untargeted
transgenic approaches, used to monitor cellular differentiation (Eiges et al.,
2001). Bacterial plasmids or viral vectors were used to randomly integrate
reporter genes, using cell-specific promoters to drive expression (Eiges
et al., 2001; Gerrard et al., 2005). Similarly, a number of fluorescent
reporter lines were generated to monitor differentiation toward specific
lineages, allowing for the identification of a variety of hESC derivatives
(Lavon et al., 2004; Singh Roy et al., 2005; Huber et al., 2007) However,
untargeted transgenic technology was soon replaced by targeted approaches
for gene editing in order to achieve specificity.
Homologous recombination (HR)-based gene editing allowed integra-
tion of a nucleotide sequence into a specific site within the hESC genome
(Mansour et al., 1988; Meyn, 1993; Giudice and Trounson, 2008). HR-
mediated methods utilize the innate DNA repair machinery of the cell to
alter or replace a specific nucleotide sequence by a homologous one
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(Leavitt and Hamlett, 2011; Brookhouser et al., 2017). Gene targeting by
HR in mESCs (Smithies et al., 1985; Thomas and Capecchi, 1987) proved
paramount for characterizing gene function and investigating human dis-
ease. However, classical methods of HR in mESCs did not prove straight-
forward in hESCs. The first report demonstrating HR-based gene editing in
hESCs targeted the X-linked, hypoxanthine-guanine phosphoribosyl trans-
ferase (HPRT) gene and pluripotency marker POU5F1 (Zwaka and
Thomson, 2003), providing key parameters for further efforts in the field,
at the time. Notably, HR-based gene targeting was also applied to correct
gene mutations in hESCs and model disease (Urbach et al., 2004; Ruby and
Zheng, 2009). Although these reports demonstrated the viability of HR-
based gene editing they also underscored the technical challenges involved.
Poor single-cell survival resulted in considerable cell death and low trans-
fection efficiencies in hESCs (Zwaka and Thomson, 2003; Urbach et al.,
2004; Irion et al., 2007; Di Domenico et al., 2008; Ruby and Zheng, 2009;
Brookhouser et al., 2017). Moreover, as recombination activity is heavily
dependent on cell type and cell cycle, applications of this method were
relatively limited (Eid and Mahfouz, 2016; Chandrasekaran et al., 2017).
Other approaches aimed at promoting HR-based targeting in hESCs
proved more successful. In the past decades, enzymatically induced DNA
double-strand breaks (DSBs) significantly increased the efficiency of HR-
mediated gene editing (Donoho et al., 1998). Genomic DSBs are gener-
ated by engineered sequence specific nucleases and repaired either by
non-homologous end-joining (NHEJ) or homology-directed repair (HDR).
The synthetic nucleases used for editing DNA in hESCs include zinc-finger
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs)
and clustered regularly interspaced short palindromic repeat (CRISPR)-
associated Cas nucleases (Chandrasekaran et al., 2017). There have been
several reports demonstrating the efficacy and value of all three
approaches for editing hPSC genomes.
ZFN applications range from the introduction of reporter genes to
monitor pluripotency and differentiation (Hockemeyer et al., 2009), to the
correction of disease-causing mutations in hiPSCs, including sickle cell
anemia (Sebastiano et al., 2011), α-thalassemia (Chang and Bouhassira,
2012) and several neurodegenerative diseases (Fong et al., 2013; Kiskinis
et al., 2014). TALENs emerged as an alternative to ZFNs, although similar
in architecture, the binding affinity and assembly of functional TALENs is
inherently more successful (Li et al., 2014). TALEN-mediated approaches
have been employed by several groups for the generation of hPSC
reporter lines (Luo et al., 2014), biallelic gene knockout and to generate
various diseases models using hiPSCs (Soldner et al., 2011; Ding et al.,
2013).
Unlike ZFNs and TALENs, limited by their high cost and poorer specifi-
city, Cas nucleases rapidly became the preferred enzymes for genome
editing due to their higher efficiency and versatility (Plaza Reyes and
Lanner, 2017). The most commonly applied Cas9 enzyme is guided by a
short single guide RNA (gRNA) molecule, which can be easily engineered.
CRISPR/Cas9 gene editing undoubtedly revolutionized human stem cell
research, providing vast opportunities for genetic manipulation, further
exemplified by the plethora of basic and translational applications to date.
To explore underlying mechanisms of gene regulation, Liao et al., for
instance, describe the targeted disruption of active DNA methyltrans-
ferases (DNMTs) in hESCs, unraveling the role of these enzymes (Liao
et al., 2015) (Fig. 1). Furthermore, gene knock-in by HDR-mediated
CRISPR/Cas has been applied for the generation of numerous reporter
lines (Balboa et al., 2017) and serves as a powerful therapeutic strategy for
the correction of specific mutant genes, as well as modeling human disease
by generating mutant hPSCs. The HDR-based approach may also be useful
in cases where generating patient-specific hiPSCs is unfeasible, creating
opportunities for studying a wide range of genetic pathologies (Zhang
et al., 2017). The CRISPR/Cas9 system has been applied for the study of
genetic diseases including Duchenne muscular dystrophy (Young et al.,
2016), Huntington’s disease (Shin et al., 2016), β-thalassemia (Xie et al.,
2014) and sickle cell anemia (Hanna et al., 2007).
Along with its success, several limitations remain to be overcome prior
to clinical applications of gene editing in hPSCs. Off target effects, resulting
from the random integration of nucleotides, still persist, while exploring
novel safe delivery strategies is also necessary (Zhang et al., 2017).
Moreover, the safety and efficacy of the edited cells require evaluation
prior to implementation in a clinical setting. Elucidating the full extent of off
target effects and improving editing efficiencies in hPSCs will require con-
stant innovation in both gene editing and stem cell research. Nevertheless,
the complementary nature of these two fields has certainly allowed
remarkable progress. Manipulating the hPSC genome to unravel gene func-
tion and underlying processes of human development will continue to
enhance stem cell technologies. Concurrently, disease modeling and thera-
peutic approaches will further foster the ultimate vision of clinical applica-
tions through personalized regenerative medicine.
Clinical trials with hPSC
Cell therapies with hPSC are emerging as a possible solution to degenera-
tive diseases. As Dr P. Andrews points out: ‘[…] it is remarkable that 20
years on from Jamie Thomson’s landmark paper, clinical trials of pluripo-
tent stem cell derivatives are in hand or on the near horizon for a range of
medical conditions […]’ (Supplementary data). hPSCs are in clinical trials
for a range of conditions, including macular degeneration, spinal cord
injury, type I diabetes, heart disease and Parkinson’s disease (Trounson,
and De Witt, 2016). About 30 clinical trials are currently ongoing with
hESC-derived cells and the first patients are being treated with hiPSC-
derived cells (Table I).
Most of the information regarding the results of clinical trials with PSCs
in this section have been obtained from sponsor company press releases
or press articles. Whenever the results arise from a scientific publication,
the reference is provided.
The first clinical trial with cells from hPSCs was launched in 2010 for
patients with spinal cord injury (Fig. 1). Geron corp. initiated a Phase I
study to evaluate the safety of the use of oligodendrocyte precursors
derived from hESCs (GRNOPC1), in patients with recent spinal cord
injury. One year later, the company canceled the trial for economic rea-
sons, reporting that no significant side effects were observed in any of the
five patients treated. In 2014, Asterias Biotherapeutics reinitiated the assay
(by renaming the product as AST-OPC1), initiating a Phase I/II trial in
which it intended to treat 35 patients with different cell doses. Preliminary
data reported by the company at the ISCCR meeting in June 2017 showed
cavitation, improved myelin coating, neovascularization and the production
of neuronal growth stimulating factors, in addition to the absence of rele-
vant side effects and good tolerance for the immunosuppressive
treatment.
In 2011, advanced cell technologies (ACTs) initiated a Phase I trial for
the treatment of age-related macular degeneration (AMD) and Stargardt’s
disease by transplantation of retinal pigmented epithelium (RPE) cells
derived from hESC (MA09-hRPE). ACT has published preliminary
(Schwartz et al., 2012) and medium term results (Schwartz et al., 2015)
without side effects and improved vision in 17 out of 18 treated patients.
Currently, ACT (which was renamed Ocata therapeutics and later Astellas
Institut for Regenerative Medicine) has four other clinical trials underway
for the treatment of macular degeneration in the USA and UK. In addition,
MA09-hRPE is also being used in two Phase I/II trials in South Korea with
similar positive results (Song et al., 2015). Dr Coffey´s group have reported
primary and secondary outcomes from the first two patients in a Phase I
clinical trial sponsored by Pfizer in the UK (da Cruz et al., 2018). One year
post-treatment, the best corrected visual acuity (BCVA) improved from
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Table I Clinical trials with cells derived from human embryonic stem cell and human-induced pluripotent stem cells.
No. Disease Cell origin Device Derived cells Sponsor Country Phase Start date Final date No. of pat. Status
NCT01217008 SCI hESC GRNOPC1 Oligodendrocytes Asterias Biotherapeutics USA I Oct-10 Jul-13 5 Completed
NCT01344993 AMD hESC MA09-hRPE Retinal pigmented epith. Astellas Inst. Regen.Med. USA I/II Apr-11 Aug-15 13 Completed
NCT01345006 SMD hESC MA09-hRPE Retinal pigmented epith. Astellas Inst. Regen.Med. USA I/II Apr-11 Aug-15 13 Completed
NCT01469832 SMD hESC MA09-hRPE Retinal pigmented epith. Astellas Inst. Regen.Med. UK I/II Nov-11 Sep-15 12 Completed
NCT01625559 SMD hESC MA09-hRPE Retinal pigmented epith. CHABiotech CO., Ltd Korea I Sep-12 Jun-15 3 Unknown
NCT01674829 AMD hESC MA09-hRPE Retinal pigmented epith. CHABiotech CO., Ltd Korea I/IIa Sep-12 Apr-16 12 Unknown
NCT01691261 AMD hESC PF-05206388 Retinal pigmented epith. Pfizer UK I Jun-15 Nov-16 10 Ongoing
NCT02057900 IHD hESC CD15+ Isl-1+ progen. Assistance Pub. Hôp. Paris France I Jun-13 Jun-18 6 Recruiting
NCT02239354 T1DM hESC VC-01™ β Cell progenitors ViaCyte USA I/II Sep-14 Jan-21 40 Ongoing
NCT02286089 AMD hESC OpRegen Retinal pigmented epith. Cell Cure Neurosciences Israel I/II Mar-15 Sep-19 15 Recruiting
NCT02302157 SCI hESC AST-OPC1 Oligodendrocits progenit. Asterias Biotherapeutic. USA I/II Mar-15 Dic-18 35 Recruiting
NCT02445612 SMD hESC MA09-hRPE Retinal pigmented epith. Astellas Inst. Regen.Med. USA I/II Jul-12 Dic-29 13 Ongoing
NCT02452723 PD phESC ISC-hpNSC Neural stem cells Cyto Therapeutics Pty Lim. Australia I Mar-16 Mar-19 12 Recruiting
NCT02463344 AMD hESC MA09-hRPE Retinal pigmented epith. Astellas Inst. Regen.Med. USA I/II Jul-12 Dic-29 11 Ongoing
NCT02464956 AMD hiPS autol Retinal pigmented epith. Moorfields Eye Hosp. NHS UK I Jul-15 Apr-16 10 Unknown
NCT02590692 AMD hESC CPCB-RPE1 Retinal pigmented epith. Regenerative Patch Tech. USA I/II Oct-15 Sep-22 20 Recruiting
NCT02749734 AMD; SMD hESC ESC-RPE Retinal pigmented epith. Southwest Hospital, China China I May-15 Dec-17 15 Recruiting
NCT02755428 AMD hESC MA09-hRPE Retinal pigmented epith. Chinese Academy Sc. China I Apr-17 Dec-20 10 Recruting
NCT02903576 AMD; SMD hESC Retinal pigmented epith. Federal Univ. São Paulo Brazil I/II Aug-15 Jun-19 18 Recruiting
NCT02923375 GVHD hiPSC allog CYP-001 MSC Cynata Therapeutics Australia I Mar-17 Sep-19 16 Recruiting
NCT02941991 SMD hESC MA09-hRPE Retinal pigmented epith. Astellas Inst. Regen.Med. UK I/II Jun-13 Dec-19 11 Ongoing
NCT03046407 AMD hESC ESC-RPE Retinal pigmented epith. Chinese Academy Sc. China I Mar-17 Dec-20 10 Recruiting
NCT03119636 PD hESC Neural precursors Chinese Academy Sc. China I/II May-17 Dec-20 50 Recruiting
NCT03162926 T1DM hESC VC-02 β Cell progenitors ViaCyte USA I Jul-17 Jun-18 15 Recruiting
NCT03163511 T1DM hESC VC-02 β Cell progenitors ViaCyte USA I/II Jul-17 Dec-20 55 Recruiting
ChiCTR-OCB-15005968 SOSD hESC Corneal epithelium Eye Institute Xiamen Univ. China I/II Oct-15 Dec-18 20 Recruiting
ChiCTR-OCB-15007054 AMD hESC ESC-RPE Retinal pigmented epith. Chinese Academy Sc. China I Jun-16 Jun-17 10 Recruiting
ChiCTR-OCB-15007055 RPD hESC ESC-RPE Retinal pigmented epith. Chinese Academy Sc. China I Sep-15 Dec-17 10 Recruiting
AMD hiPSC allog Retinal pigmented epith. RIKEN Center for Dev.Biol Japan I Feb-17 5 Recruiting
UMIN000011929 AMD hiPS autol Retinal pigmented epith. RIKEN Center for Dev.Biol Japan I Sep-14 Sep-15 1 Suspended
PD hiPSC allog Dopamine-secreting nerve Center for iPS Cel Res. Japan I 2018
hESC, human embryonic stem cell; hiPSC, human-induced pluripotent stem cell; MSC, mesenchymal stem cell; allog, allogenic; epith, ephitelial; progen, progenitors; pat, patient; autol, autologous.
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10 to 39 and from 8 to 29 letters in Patients 1 and 2, respectively. Reading
speed improved from 1,7 to 82,8 and from 0 to 47,8 words/min.
In an article published recently in Ophtalmology (Mehat et al., 2018), the
authors did not find any evidence of uncontrolled proliferation or inflam-
matory responses after the transplantation. Borderline improvements in
BCVA in four participants either were unsustained or were matched by a
similar improvement in the untreated contralateral eye. Microperimetry
demonstrated no evidence of benefit at 12 months in the 12 participants.
Other clinical trials for the treatment of macular degeneration by hESC-
derived RPE have been registered such as those carried out by Pfizer (UK),
Regenerative Patch Technologies (USA), Cell Cure Neurosciences (Israel),
Federal University of São Paulo (Brazil), Chinese Academic of Science
(China), Southwest Hospital, Chongqing (China), all registered at Clinical
Trials.gov (https://clinicaltrials.gov). In the Chinese Clinical Trial Register
(www.chictr.org), there are two clinical trials for macular degeneration
from The Chinese Academy of Sciences and one trial from The Eye
Institute of Xiamen University with corneal epithelium derived from hESCs
for severe ocular surface disease.
In 2013, the first Phase I clinical trial for the treatment of six patients
with cardiac ischemia with cardiac progenitors derived from hESCs was
started in the Assistance Publique Hôpitaux in Paris. The preliminary
results of the first treated patient were published by Menasche et al.
(2015) and reported an improvement of cardiac function and absence of
important side effects.
In 2014, a Phase I/II study for the treatment of 65 patients with type 1
diabetes was initiated by Viacyte. A device (VC-01) consisting of a semi-
permeable membrane that encapsulates the β cell progenitor cells had
been designed. This device, implanted subcutaneously, allows the entry of
oxygen and nutrients, as well as the release of insulin and other hormones,
while protecting the cells from the autoimmune reaction that causes type
1 diabetes. The company announced in August 2017 two more trials with
a modified device (VC-02) that allows direct vascularization into itself.
In 2017, the Australian company Cyto Therapeutics Pty Limited initiated
a study in 12 patients with Parkinson’s disease with neuronal progenitors
from parthenogenetic hESCs (ISC-hpNSC). After 6 months of treatment, a
reduction of the off period was observed in the treated patients, as well as
an improvement in motor and cognitive abilities. Another clinical trial for
Parkinsons’s disease had been announced in June 2017 by The Chinese
Academy of Sciences consisting of the transplantation of neuronal precur-
sors derived from hESCs (50 patients; Phase I).
In 2014, the Riken Institute in Japan treated a patient with cells obtained
from hiPSCs for the first time (Fig. 1). These were RPEs derived from
autologous hiPSCs to avoid immune rejection. The patient did not present
any side effects after the treatment. The trial was suspended when
attempting to treat a second patient as mutations were detected in the
generated hiPSCs (Mandai et al., 2017). Due to these findings and to the
fact that the generation of patient-specific iPSCs is time-consuming and
expensive, Riken opted for the use of tested and safe allogenic hiPSCs. A
new clinical trial has been initiated involving the generation of a hiPSC bank
from peripheral blood samples with the most frequent homozygous HLA
haplotypes that could match a sufficient proportion of the general popula-
tion (Okita et al., 2011b). Riken announced the treatment of the first
patient with RPE derived from allogeneic hiPSCs in February 2017.
The Moorfields Eye Hospital NHS Foundation Trust (UK) reported in
May 2015 that the first AMD patient was treated with hiPSC-derived RPE.
To date, no results have been published so far.
Cynata Therapeutics (Australia) started a clinical trial in May 2017 with
mesenchymal cells from allogeneic hiPSC (CYP-001) for the treatment of graft
versus host disease (GVHD). Improvement in the severity of the GVHD in
the first eight patients was announced in January 2018. The Center for iPS
Cell Research in Japan reported in February 2017 that a trial for the treatment
of Parkinson’s with allogeneic hiPSCs will soon be conducted.
Clinical trials registered in Clinical Trials.gov and other registries are
shown in Table I.




In January 2014, two Nature papers seemed to revolutionize stem cell
derivation by showing that somatic cells could be ‘reprogrammed’ to
PSCs simply by subjecting them to certain types of stress, e.g. submer-
sion in weak acid, physical trauma or bacterial toxins. However, within
weeks of the paper’s publication errors were reported and scientist
trying to replicate this stimulus-triggered acquisition of pluripotency
(also known as STAP) method all failed. Lead author Dr H. Obokata
was accused of misconduct and in August 2014 the papers were
retracted.
Human SCNT embryos
Dr W. Hwang and his former colleagues at Seoul National
University, South Korea claimed in 2004 and 2005 to have produced
human SCNT embryos and the successful derivation of ESCs. This
purported breakthrough was published in Science, however both
papers were soon retracted based on suspicions of fraud. The ball
started rolling when it was found that two female scientists in the lab
donated eggs for this research, a violation of international ethics
guidelines. The scientific claims were further examined and the final
report from the investigation committee of Seoul National University
concluded that the authors of the two papers published in Science
engaged in research misconduct, with the papers containing fabri-
cated data. Once considered a national hero in South Korea, receiv-
ing huge financial support from the government, Dr W. Hwang
became an outcast.
Conclusion
The first 20 years following the derivation of hESCs have proven rich in
developments. The multi-disciplinary nature of the field with tremen-
dous potential for a vast range of diagnostic and therapeutic applica-
tions has been generating immense excitement in medical research.
From the derivation of iPSCs to the discovery of different states of
pluripotency, and the refinement of differentiation protocols and gene
editing technologies. At present, several clinical trials are underway
and preliminary results are promising. In the years to come, pluripo-
tent cells will come of age, and regenerative therapies in several fields
of medicine will profit from the production of highly defined cell popu-
lations in clinical grade conditions. Although the road to the seamless
application of pluripotent human cells in the clinic is still treacherous,
exceptional advancement in just 20 years provides a positive outlook
on the future of this discipline. To conclude with the words of
Dr P. Andrews: ‘Predicting the future is always dangerous and the only
certain thing is that we will use stem cell biology in the future in ways
that we do not imagine today.’
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SUPPLEMENTARY DATA
INTERVIEWS WITH PIONEERS IN THE STEM CELL
FIELD OF RESEARCH
Shinya Yamanaka
Center for iPS Cell Research and Application, Kyoto University,
Japan and Gladstone Institute of Cardiovascular Disease, Gladstone
Institutes, San Francisco, CA, USA
Q: Please tell us about the iPSC experiments leading to
the influential articles in Cell 2006 and 2007. How did it hap-
pen?Were the results as expected? How long did it take? etc
A: I got extremely excited when I first read James Thomson’s paper
on human ES cells because of their huge potential in regenerative
medicine. Because of the work, I started a project to make pluripotent
stem cells from adult human cells instead of embryos.
I first expected it would take a few decades to achieve the goals but
thanks to the talented students and staff, previous research and data-
base, we successfully generated mouse iPS cells in 6 years. Repetitive
experiments gave us confidence in our achievement. From mouse to
human, it took almost two decades with ES cells. However, thanks to
human ES cells, we knew exactly how we should culture human iPS
cells. Because of this it took less than a year with iPS cells.
Q: How has the iPSCs influenced the field of stem cells in
your opinion?
A: I believe that the biggest advantages of iPSCs is that we can gen-
erate pluripotent stem cells from patients or healthy individuals with
solid medical history.
Q: What does the future hold for pluripotent stem cells?
What are the major hurdles at the moment?
A: Clinical trials using pluripotent stem cells in some diseases are
already ongoing and much more are expected to follow them. We
need to carefully see whether these trials will turn out to be safe and
efficient, and I hope the fruits will contribute to new treatments as
soon as possible.
iPS cell technology is also expected to pioneer new basic research such
as elucidating the mystery of life and conservation of endangered species.
One of the big questions to puzzle out is the mechanism of repro-
gramming. In terms of iPS cells, how we can evaluate safety and qual-
ities of iPS cells and iPS cell-derived differentiated cells is another
question we need to answer.
Q: Could you tell us an anecdote related to your work with
pluripotent stem cells?
A: When we first invented ES cell-like cells from mature cells, I
named them ‘induced pluripotent stem cells’ abbreviated as iPS cells.
In naming iPS cells, I used a small letter for ‘i’ after the model of ‘iPod’,
hoping that the name would be easy to be remembered.
Alan Trounson
Hudson Institute of Medical Research and Monash University,
Clayton, Victoria, Australia.
Q:What have been the main results of your work?
A: We had been working on development of hESCs from human
blastocysts while I was on sabbatical leave 1994–5 with Ariff Bongso in
Singapore. We were growing these lumpy colonies that looked differ-
ent from mouse ESCs. I asked the mouse ESC experts and they
thought that they had differentiated. This wasn’t in fact the case.
When Martin Pera joined me from Oxford he thought we had human
ESCs, so I sent Ben Reubinoff (our PhD student) to Singapore to make
them again. He brought back some of the colonies which converted to
hESCs and we set about characterizing them using markers Martin had
setting up the teratoma assays. Then Jamie Thomson paper arrived in
1998 for reviewing for the journal Science—the establishment of
human ESCs. We knew he was right because we had them in the lab
but had not as yet characterized them as teratomas. We went on to
show you could direct them into the neural lineage in our paper in
Nature Biotech in 2000. We had made these hESCs from a small num-
ber of donated blastocysts grown in Arrif Bongo’s lab.
Q:What have been the consequences for the field?
A: This work showed that we could develop immortal pluripotent
stem cells that had the potential to be very important in cell therapy
and drug discovery. Clinical trials using these cells have begun in work
to repair spinal cord injury, macular degeneration, heart disease, type I
diabetes and Parkinson’s Disease (see Trounson & DeWitt, Nature
Reviews Molecular Cell Biology 17: 194–200, 2016). They were also
critical in working out the transcription factors needed to make iPSCs
from somatic cells and now for new developments in drug discovery
(see: Zhang et al. Cell Stem Cell 21: 161–65. 2017).
Q: How do you foresee the future in this field?
A: I think we shall see many new developments and among them
those that have good evidence for progress include:
• The use of pluripotent stem cells for the targeted destruction of
cancer stem cells - an area I am working on myself with a group of
colleagues (see: www.Catherics.com.au).
• Gene editing oocytes and embryos to remove inherited genetic
diseases.
• The use of blastocyst complementation to form human organs for
transplantation.
• The development of artificial ovaries for sterile women or those at
risk of reproductive sterility due to cancer therapies.
• Development of synthetic embryos for study of the human stem
cell differentiation and organization of the human developmental
processes.
• Production of human gametes via iPSCs or their derivatives for
research and possible clinical applications.
Outi Hovatta
Emerita Professor, Karolinska Institutet, Stockholm, Sweden
Q: How did you get into the field of stem cells? Please tell
us about the embryonic stem cell derivations. How did it
happen?Were the results as expected? How long did it take?
etc
A: I was leading a large in vitro fertilization (IVF) unit at Karolinska
University Hospital in Stockholm, Sweden, since 1998. At that time,
there was a wide discussion regarding human embryonic stem cells
(hESC). In Sweden, the attitudes were accepting also ethically, thinking
of the large potential benefits in regenerative medicine. Hence, we
obtained ethics approval for establishing hESC lines from donated
embryos that could not be used in infertility treatment. We saw that
the hESC lines derived using mouse cells as feeder cells, and using
bovine serum and other ingredients with animal origin in the culture
medium, were quite suboptimal in quality thinking of infection risks
and functional quality in clinical work.
Hence, we decided to develop better derivation systems.
Q: What do you think is the main achievement of your
work?
A: In our team, we developed a completely animal substance free
chemically defined derivation and culture systems for hESC. We took
them to Good Manufacturing Practice (GMP) grade laboratory. We
now have hESC lines that fulfill the requirements for clinical treatment.
Q:What do you think is next in this field?
A: hESC can already now be differentiated to many cell types, such
as retinal pigment epithelial cells, dopamine producing neurons and
motor neurons for clinical treatment. In the near future these cells be
used in clinical trials and treatment.
PeterWAndrews
Centre for Stem Cell Biology, Department of Biomedical Science,
The University of Sheffield, Sheffield S10 2TN, UK
Q: How did you get in the field of stem cells?
A: My introduction to pluripotent stem cells came in 1974 when, for
my first postdoc position, I joined the group of François Jacob at the
Institut Pasteur in Paris, studying mouse embryonal carcinoma (EC)
cells, the malignant predecessor of embryonic stem cells. After a short
interlude I moved to the Wistar Institute in Philadelphia in 1978
where, working with Barbara Knowles and Davor Solter, we set out to
characterize the equivalent human EC cells as tools for studying human
development biology, though human and mouse EC cells proved
somewhat different in certain respects.
Q: What do you think is the main achievement of your
work?
A: From the point of view of the field, probably the most impact has
come from my early work characterizing the key cell surface marker
antigens of human EC and ES cells, particularly SSEA3, SSEA4,
TRA-1–60 and TRA-1–81, and then later from finding that human ES
cells in culture are subject to non-random karyotypic changes that
mimic similar changes typical of EC cells, their malignant counterparts.
However, from my own point of view, maybe the most satisfying was
finding that the pluripotent human EC cell line, NTERA2, differentiates
in response to retinoic acid, a result that was used later to show that
retinoic acid induces HOX gene expression in a concentration depend-
ent manner, that is co-linear with the positions of the genes in the
HOX gene cluster and with the anterior posterior embryonic axis.
Q: What do you think is next in this field? What is, accord-
ing to you, the future of stem cells?
A: Predicting the future is always dangerous and the only certain
thing is that we will use stem cell biology in the future in ways that we
do not imagine today. Nevertheless, it is remarkable that 20 years on
from Jamie Thomson’s landmark paper, clinical trials of pluripotent
stem cell derivatives are in hand or on the near horizon for a range of
medical conditions, including macular degeneration, Parkinson’s dis-
ease and diabetes, while other applications are in development. If
these are successful, however, it will still take quite a few years to
convert them to routine, affordable treatments. On the other hand,
may be the greatest, more immediate impact of stem cell biology will
come from the use of stem cell derivatives in disease modeling, and
drug discovery.
Miodrag Stojkovic
Faculty of Medical Sciences, Department of Genetics, University of
Kragujevac, 34000 Kragujevac, Serbia. Spebo Medical, Leskovac, Serbia.
Q: How did you get in the field of stem cells? Anecdotes
are welcome!
A: Before I moved to England in 2002, I was working at Munich’s
University. Germany at that time had very conservative and restrictive
policies for human embryos and human embryonic stem cell (hESC)
research. One day I was reading Nature Jobs and found that NHS and
Newcastle Fertility Centre are looking for a research embryologist
who will be responsible for derivation of hESC using surplus and
donated embryos. I started there but working conditions for deriv-
ation were more than modest: one fridge, one stereomicroscope and
one incubator, no laminar flow, no centrifuge, no UV light microscope.
I started with the work, but after several months I had to go abroad
and asked my wife Petra to change media since I noticed some small
outgrowth of inner cell mass cells. When I went back the colony was
bigger and I remember very well the following picture: in the front of
our microscope was Thomson’s paper and images of hESC colonies
and Majlinda Lako and myself starting our open-air work: cutting the
colony, passaging the cells… both of us had never seen or worked
with hESC before. Nevertheless, the first hES-NCL1 line was born and
it was the first fully characterized UK line. In mid 2004, hES-NCL1 and
King’s College line were the first approved research grade lines for
depositing in the UK Stem Cell Bank. Free of contamination and myco-
plasma. And after that I got a new contract, readership, then profes-
sorship… and many laminar flows!
Q: What do you think is the main achievement of your
work?
A: I’m very proud that we derived many more lines, including the
first line from arrested, non-developing embryos, also to clone the first
human blastocyst, to develop protocols for growth and targeted differ-
entiation of hESC while we were at the same time fighting for open
and transparent science, but also, that based on this work, the small
lab became a huge centre for stem cell biology and cellular therapy.
Own scientific achievements are important but it also makes me more
happy to see that so many young scientists worldwide use hESC as an
irreplaceable and unique tool to learn about normal and abnormal
human development, pluripotency, reprogramming, differentiation,
improving at the same time tissue engineering, regenerative medicine,
testing new chemicals and drugs…
Q: What do you think is next in this field? What is, accord-
ing to you, the future of stem cells?
A: Besides of all the already mentioned fields, stem cells will con-
tinue to spread
and ‘occupy’ more and more labs and help to address different
issues including repair and creation of organs, cancer stem cell biology,
and the complexity of immunology.
Shoukhrat Mitalipov
Center for Embryonic Cell and Gene Therapy, Oregon Health &
Science University, Portland, OR, USA.
Division of Reproductive & Developmental Sciences, Oregon
National Primate Research Center, Oregon Health & Science
University, Beaverton, OR, USA.
Q:What was the main result of your work. How did it hap-
pen? (Anecdotes are welcome)
A: We demonstrated that cytoplasmic factors present in mature human
oocytes are capable of converting the transplanted nuclear genomes from
somatic cells (skin fibroblasts) to become ‘oocyte-like’. We then used
such skin-derived oocytes to develop into blastocysts and ESCs.
Q: What have been the consequences of your work in the
field?
A: Our study was reproduced within a year by two labs signifying
that our human SCNT protocols are real.
Q: What do you think is next in this field (future
perspectives)?
A: I believe the most immediate application of human SCNT is gen-
erating haploid oocytes for treatment of female infertility.
Thank you so much for including us in your interview.
